Brightech International Report issue

For profit Phase 3
Founded: Somerset NJ United States (2002)

Organization Overview

First Clinical Trial
2020
NCT04285086
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Brightech International

Active Ingredients

Drugs in Phase 3 Trials (1)

interferon alpha-2b (Intron-A) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Thrombocythemia, Essential (Phase 3)

Thrombocytosis (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 1
  • # of Trial APIs: 1